ScholarIQanswers from OpenAlex & ORCID
Terufumi Kato
ResearcherPublications, citations & collaboration network
Terufumi Kato is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Terufumi Kato have?
ScholarIQindexed works
Terufumi Kato has 521 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Terufumi Kato have?
ScholarIQcitation count
Terufumi Kato has 30,632 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Terufumi Kato?
ScholarIQh-index
Terufumi Kato has an h-index of 58 in OpenAlex.
What is the i10-index of Terufumi Kato?
ScholarIQi10-index
Terufumi Kato has an i10-index of 175 in OpenAlex.
What is the ORCID of Terufumi Kato?
ScholarIQorcid
The ORCID for Terufumi Kato is on the source record.
What is the OpenAlex record for Terufumi Kato?
ScholarIQopenalex
The OpenAlex for Terufumi Kato is on the source record.
What are the most-cited papers on Terufumi Kato?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf, Antoîne Italiano, Martin Schüler, Hossein Borghaei, Fabrice Barlési, Terufumi Kato, Alessandra Curioni‐Fontecedro, Adrian G. Sacher, Alexander I. Spira, Suresh S. Ramalingam, Toshiaki Takahashi, Benjamin Besse, Abraham Anderson, Agnes Ang, Qui Tran, Omar Mather, Haby Henary, Gataree Ngarmchamnanrith, Gregory Friberg, Vamsidhar Velcheti, Ramaswamy Govindan
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist